Výsledky vyhledávání - "Richard Newmark"

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease

Autor: Severine Vermeire, Yi-Hsiang Hsu, Stephan R. Targan, Chris B. Russell, Brian G. Feagan, Carol J. Landers, Dalin Li, Remo Panaccione, Shao-Lee Lin, Richard Newmark, Gil Y. Melmed, Nan Zhang, Yun Chon, Paul Klekotka

Publikováno v: The American journal of gastroenterology. 111(11)

To assess the safety and efficacy of brodalumab, a human anti-interleukin-17 receptor monoclonal antibody, in patients with moderate-to-severe Crohn's disease (CD).Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1eded7eb777dd1b6b82d221d05ecbe6
https://pubmed.ncbi.nlm.nih.gov/27481309

Zobrazit plný text záznamu

Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients

Autor: A. Deodhar, Wayne Tsuji, Charles Peterfy, L. Zhou, P Ory, R. Trapp, W. Shergy, J. Schechtman, Richard Newmark, H. Wang, D. Mandel, R. K. Dore, T. Fuerst

Publikováno v: Arthritis Care & Research. 62:569-574

Objective Periarticular osteoporosis is one of the earliest radiographic signs of bone damage in rheumatoid arthritis (RA). Denosumab, an investigational fully human monoclonal antibody that binds to RANKL, inhibits bone erosion and systemic bone los

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01fb998dedcc5b4ce57df08e10e6242f
https://doi.org/10.1002/acr.20004

Zobrazit plný text záznamu

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

Autor: Robin K, Dore, Stanley B, Cohen, Nancy E, Lane, William, Palmer, William, Shergy, Lifen, Zhou, Huei, Wang, Wayne, Tsuji, Richard, Newmark, Michel, Zummer

Publikováno v: Annals of the Rheumatic Diseases. 69:872-875

Objectives To report results of subgroup analyses of bone mineral density (BMD) and bone turnover markers from a randomised, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor, in patients with rheumatoi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceadbaa9ebb47e69ed6ecb6397ecea15
https://doi.org/10.1136/ard.2009.112920

Zobrazit plný text záznamu

A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate

Autor: Yun Chon, Karel Pavelka, Scott Baumgartner, Richard Newmark, Shao-Lee Lin, Ngozi Erondu

Publikováno v: The Journal of rheumatology. 42(6)

Objective.To evaluate the efficacy and safety of brodalumab, a human monoclonal antibody inhibitor of the interleukin 17 receptor, in subjects with rheumatoid arthritis (RA).Methods.Patients (n = 252) with inadequate response to methotrexate (MTX) we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97db6883eadc80e6e3fda6d2dbe7a7ec
https://pubmed.ncbi.nlm.nih.gov/26034153

Zobrazit plný text záznamu

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

Autor: Pirow Bekker, Sean Robbins, Stanley Cohen, Larry W. Moreland, Deborah Lium, Mark C. Genovese, Richard Newmark

Publikováno v: Arthritis & Rheumatism. 50:1412-1419

Objective To determine the potential for additive or synergistic effects of combination therapy with the selective anti–tumor necrosis factor α agent etanercept and the anti–interleukin-1 agent anakinra. Methods Two hundred forty-four patients i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a67a471c39b2a93f37d060fc17d5811a
https://doi.org/10.1002/art.20221

Zobrazit plný text záznamu

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

Autor: André D. Beaulieu, Maria Greenwald, Ajay Nirula, Christopher T. Ritchlin, Ngozi Erondu, Philip J. Mease, Mark C. Genovese, Jing Yuan Feng, Richard Newmark, A. A. Deodhar

Publikováno v: The New England journal of medicine. 370(24)

We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis.We randomly assign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98785e4b0128dfb064f166a27d56f3e3
https://pubmed.ncbi.nlm.nih.gov/24918373

Zobrazit plný text záznamu

Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis

Autor: Wayne Tsuji, Richard Newmark, H. Wang, P Ory, Cristina Harper-Barek, John T. Sharp

Publikováno v: Arthritis careresearch. 62(4)

Objective Osteoclast-mediated bone loss in the hand predicts future bone erosions in patients with rheumatoid arthritis (RA). Osteoclast activity depends on RANKL, which is inhibited by denosumab, an investigational fully human monoclonal antibody ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c4f385c1b1d856e08b7590bfca13f45
https://pubmed.ncbi.nlm.nih.gov/20391509

Zobrazit plný text záznamu

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

Autor: Jacques P. Brown, Richard Newmark, Jose M. Álvaro-Gracia, Luiz H. De Gregorio, Henry G. Bone, Chad L. Deal, Robert R. Recker, Rachel B. Wagman, Peyman Hadji, Richard L. Prince, M. Austin, H. Wang, Lorenz C. Hofbauer, Javier San Martin, Douglas P. Kiel, Cesar Libanati

Publikováno v: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 24(1)

Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, a key mediator of osteoclast formation, function, and survival. This phase 3, multicenter, doubleblind study compared the efficacy and safety of denos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0495e5394c932a394e4302eb40c8265
https://pubmed.ncbi.nlm.nih.gov/19092832

Zobrazit plný text záznamu

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

Autor: Stanley B, Cohen, Robin K, Dore, Nancy E, Lane, Peter A, Ory, Charles G, Peterfy, John T, Sharp, Désirée, van der Heijde, Lifen, Zhou, Wayne, Tsuji, Richard, Newmark, Michel, Zummer

Publikováno v: Arthritis and rheumatism. 58(5)

Objective RANKL is essential for osteoclast development, activation, and survival. Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting its activity. The aim of this multicenter, randomized, double-blind, placebo-controlle

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1d7ecb2ecc03415f736e4603851e6f8
https://pubmed.ncbi.nlm.nih.gov/18839011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání